Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

We conducted an institutional study to compare the clinical and pathological efficacy between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle albumin–bound paclitaxel plus gemcitabine (nab‐P/G) for borderline resectable pancreatic cancer (BRPC) and locally advanced pancreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Adam R., Prabhakar, Dhivya, Yildiz, Vedat O., Cloyd, Jordan M., Dillhoff, Mary, Abushahin, Laith, Alexandra Diaz, Dayssy, Miller, Eric D., Chen, Wei, Frankel, Wendy L., Noonan, Anne, Williams, Terence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333854/
https://www.ncbi.nlm.nih.gov/pubmed/32415696
http://dx.doi.org/10.1002/cam4.3075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333854/
https://www.ncbi.nlm.nih.gov/pubmed/32415696
http://dx.doi.org/10.1002/cam4.3075

Ejemplares similares